FGF21 and metabolic dysfunction-associated steatohepatitis: Although, the plasmin inhibitor PAI‐1/SERPINE1 was up‐regulated in patients with increased FGF21 expression, a meta‐analysis showed PAI‐1 blood levels in MASH not to differ from healthy controls.66